Edge of Life builds slowly toward something two doctors cannot quite name, something that resists clinical language altogether and is, by any honest reckoning, a spiritual experience. I watched it in a sold-out cinema with ninety-something other people who work at the edges of dying.
FanForce approached me about hosting a screening, and I brought the idea to my local end-of-life doula collective. We made it happen together. The audience was spiritual care practitioners, end-of-life doulas, and others drawn to questions about spirituality, dying, and psychedelic-assisted therapy. It was exactly the right room for this film.
About the film and the trial
Directed by Lynette Wallworth, Edge of Life is built around an Australian-first clinical trial at St Vincent’s Hospital Melbourne, led by clinical psychologist Dr Margaret Ross and psychiatrist Dr Justin Dwyer. A note for transparency: I’m on the Pastoral Care team at St Vincent’s, but I was not employed there when the trial took place, nor have I worked at the particular site where it was conducted. I’m speaking only for myself here.
The film follows two women with metastatic cancer, Flavia and Ros, as they move through the trial. It is their experience, and that of Flavia’s husband, who accompanies her, that gives the film its emotional centre. The trial itself was broader, exploring psilocybin-assisted therapy across a range of advanced, life-limiting illnesses, and was the first in the world to include patients with non-malignant conditions such as motor neurone disease and advanced cardiac failure. The published findings report rapid and sustained reductions in depression and anxiety, as well as “enhanced spiritual well-being, quality of life, and significant reductions in demoralisation, death anxiety and hopelessness.”
Where science meets the numinous
Edge of Life is less about the clinical trial itself and more about the tension between science and spirituality. Dwyer carries this tension most visibly. He is trained to measure, to account for, and to remain within the structures of evidence-based medicine. His patients describe something he has no clinical framework for: encounters with meaning, with connection, with something that exceeds the self.
From where I sit, as someone whose spiritual life is not incidental to how I understand the world, this is one of the most interesting things the film captures. It’s not the conflict between science and spirituality, which is, in many ways, a false binary and an old debate, but the moment when a materialist framework meets the genuinely numinous and quietly begins to strain.
As people approach dying, the limits of clinical frameworks become clear: symptom management does not always address fear or existential distress. The trial suggests psilocybin-assisted therapy may help people reorient to death, not just endure it. This raises the deeper question: how do we best support these profound experiences?
The clinical, spiritual, and capitalist containers
In the clinical setting, the container is carefully constructed: a synthesised compound, a controlled environment, trained therapists, safety protocols, and ethics committees. There is real care in this. But the film also takes us to the Amazon, to the Yawanawá people, where Dwyer and Ross travelled to experience traditional uses of plant medicines firsthand, guided by the shaman Muka. The container looks entirely different here. The medicine is gathered, prepared, and sung over. The experience is held within a web of community, of lineage, of long-standing relationship with land and with the non-human world. The authority of the facilitator comes not from a credential but from responsibility to the community, to the medicine, to the ancestors who tended this knowledge before them. Integration is not a scheduled session afterwards; it is woven into the fabric of communal life.
The sacred tree of the Yawanawá is the ceiba. For those of us who move in traditions where the ceiba is also held as sacred — it appears in Lukumí practice, among others — there is something quietly striking about seeing it at the centre of this story. Plant medicines, like sacred trees, carry meaning that travels. The question is whether the containers we build are worthy of what they hold.
When plant medicines move from their ceremonial context into a clinical protocol that strips them of song, community, and the relational web that gives them meaning, something is inevitably lost. The clinical model offers safety and rigour, and those matter, but it does not yet offer belonging. A person can move through a well-run psychedelic session and still face their death alone, in a system that closes the door once the integration paperwork is done. What might it look like to bring something of that communal holding, the ongoing presence, and the tending into clinical care?
Spiritual Carers work at exactly this intersection, accompanying people through existential and spiritual crisis, holding space for experiences that exceed clinical language, sitting with what cannot be fixed. The film acknowledges, through its journey to the Amazon and its relationship with Muka, that something beyond clinical expertise is needed to hold these experiences well. And yet Spiritual Carers do not appear in the film, and are not mentioned in the published trial findings. When someone undergoes a profound spiritual experience as part of their dying process, who is tending to them?
Outside these two contexts lies a third space: the commercialisation of psychedelic experiences. Here, people seek out something meaningful, but often encounter a diluted approximation: retreat centres, facilitators without lineage or accountability, experiences marketed as transformative, held in containers assembled last week, and without the communal structures that support integration afterwards. This is where the colonial echo is loudest: plant medicines extracted from their traditions, repackaged for a paying clientele, and severed from the responsibilities that made it coherent in the first place. The psychological, financial, and ethical risks of this unregulated space are real, and the absence of oversight leaves vulnerable people with very little recourse when things go wrong.
The film doesn’t dwell here. Perhaps it shouldn’t, given its focus. But for those of us thinking about what psychedelic-assisted therapy might look like at scale, it’s a question that shouldn’t be deferred.
Who will access psychedelic-assisted therapy
Even through legitimate channels, this therapy is not easily accessible or inexpensive. The clinical trial was rigorous, resource-intensive, and conducted at a major tertiary hospital. The therapy model requires trained personnel, extended preparation and integration sessions, and a therapeutic relationship built over time. It is not something that can be easily scaled or cheaply delivered.
Dwyer himself, speaking during a 2023 RANZCP webinar about the move into private practice, suggested that a caseload of one patient a month is more realistic than the ambitions of some proposed clinics. He raised hard questions about where trained therapists will come from, how they will be supervised, and who can afford private treatment that may cost tens of thousands of dollars.
As with so many emerging interventions, there is a real risk that what is framed as a breakthrough in care becomes available primarily to people who can afford it, live near the right institutions, or present as the right kind of patient. It is a question for the systems into which this work will eventually land.
See the film
What the film returns me to, in the end, is that dying is not only a medical event. It is a passage with emotional, relational, existential, and, yes, spiritual dimensions. Cultures that have maintained continuous relationships with death through ceremony, through community, through the tending of ancestors have always known this. Modern Western medicine, for all its extraordinary capacities, developed largely by setting this knowledge aside. Edge of Life is interesting partly because it shows that knowledge quietly reasserting itself.
The film doesn’t resolve the tension between measurement and meaning, between the clinical and the sacred. It isn’t trying to. It asks what happens when those worlds meet and what kind of care might be required when they do.
Edge of Life is a well-made film: thoughtful and unhurried, with a lightness that keeps it from becoming heavy, and moments of humour that make the harder material breathable. The audience found it gentle, beautiful, and inspiring, sparking conversations long after the credits rolled. I’ve now seen it twice and will see it again.
For those in end-of-life care, this is familiar ground. We work at that edge every day.
Edge of Life has a running time of 110 minutes (1 hour and 50 minutes). Currently, you can watch it on various streaming sites or organise your own cinema screening via FanForce.
A very interesting read, Cosette. I sensed the act of medicalisation of this (the “science”), lost some of the “art” of organic nature, tradition, and a true sense of community. I am sure there will be lots of discussion as the use of psilocybin-assisted therapy in mainstream Western society is further explored. It would be interesting to know how this therapy impacts persons who ARE more comfortable with dying, along with those who fear death and dying. Thanks for sharing.
Thanks for reading and commenting, Jacqui. Your question about the impact on psilocybin-assisted therapy on people who are more comfortable with dying is interesting. At the moment, I think the primary conditions approved are treatment-resistant depression and end-of-life distress. Emerging areas include addiction, OCD, and PTSD.